485 Results (Page 10 of 20)
China Markets Research Reports
China Epigenetics Market Analysis
China Epigenetics Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Factors driving this market growth include an increase in the incidences of infectious diseases, cancer, chronic conditions, and genetic conditions; rising healthcare spending, which, according to the American Medical Association, will exceed $187.6 billion in 2021; and growing interest in bioinformatics, the market for which will reach $10 billion in revenue in 2022. Global key players in the epigenetics market include Illumina Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Merck KGaA, and Abcam plc.
China Epilepsy Drugs Market Analysis
China Epilepsy Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rising prevalence of epilepsy, increasing incidences of brain cancer in the geriatric population, and extensive research and development (R&D) activities represent some of the key factors driving the market. Some of the prominent global players in the epilepsy drugs market include Pfizer Inc., UCB S.A., GlaxoSmithKline plc, Novartis AG, and Eisai Co., Ltd.
China Gastroesophageal Reflux Disease (GERD) Drugs Market Analysis
China Gastroesophageal Reflux Disease (GERD) Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The high prevalence of GERD, rising awareness and diagnostic rates, technology improvements, and lifestyle variables are all driving factors in the Gastroesophageal Reflux Disease (GERD) medications market. Some prominent global players in the Gastroesophageal Reflux Disease (GERD) drugs market include AstraZeneca PLC, Pfizer Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, GlaxoSmithKline plc, Eli Lilly and Company, AbbVie Inc., Mylan N.V., Perrigo Company plc, and Sun Pharmaceutical Industries Ltd.
China Gastrointestinal Drugs Market Analysis
China Gastrointestinal Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rising prevalence of gastrointestinal problems, caused by factors such as changing lifestyles, dietary habits, and an ageing population, is one of the main drivers for gastrointestinal medications. Technological advances in drug research and targeted medicines, which provide more effective treatment alternatives, also contribute to market growth. Furthermore, as people become more aware of and diagnose gastrointestinal diseases, the need for medications to treat these conditions grows. Pfizer Inc., Johnson & Johnson, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, GlaxoSmithKline plc, Bristol Myers Squibb Company, Eli Lilly and Company, Merck & Co., Inc., and Allergan plc are among the major global competitors in the gastrointestinal drugs market.
China Generic and Biosimilar Pharmaceutical Market Analysis
China Generic and Biosimilar Pharmaceutical Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The generic and biosimilar pharmaceutical market is driven by cost-effectiveness, patent expirations, rising healthcare demand, and government cost-cutting initiatives. Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH (Novartis), Pfizer Inc., Amgen Inc., Biocon Ltd., Dr. Reddy's Laboratories Ltd., Fresenius Kabi AG, Celltrion Inc., and Stada Arzneimittel AG are global companies in the Generic and Biosimilar Pharmaceutical Market.
China Glaucoma Drugs Market Analysis
China Glaucoma Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The increasing prevalence of glaucoma, caused by factors such as an ageing population and rising awareness, is a driver of the glaucoma medications industry. Drug delivery system technological improvements help to increase treatment choices. Novartis AG, Pfizer Inc., Santen Pharmaceutical Co., Allergan (AbbVie Inc.), Bausch Health Companies Inc., Alcon (a part of Novartis AG), Merck & Co., Aerie Pharmaceuticals, Sun Pharmaceutical Industries Ltd., and Santen Inc. are the global players in the Glaucoma Drugs Market.
China Glucagon Like Peptide-1 (GLP-1) Receptor Agonist Market Analysis
China Glucagon Like Peptide-1 (GLP-1) Receptor Agonist Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Key drivers of the GLP-1 receptor agonist market include their efficacy in controlling blood sugar levels, additional benefits like weight loss and cardiovascular risk reduction, rising prevalence of type 2 diabetes, and increasing awareness of diabetes management, leading to growing demand for these medications. Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca plc, Sanofi S.A., Merck & Co., Inc., Boehringer Ingelheim International GmbH and Zealand Pharma A/S are global key players in the market.
China Asthma and COPD Therapeutics Market Analysis
The China Asthma and COPD Therapeutics Market was valued at US $2.68 Bn in 2022, and is predicted to grow at (CAGR) of 6.70% from 2023 to 2030, to US $4.51 Bn by 2030. The key drivers of this industry include the surge in the prevalence of COPD and asthma, rising economic growth, advancements in therapeutics, and others. The industry is primarily dominated by players such as AstraZeneca, Novartis, Yuhan, GSK, Hengan, and Boehringer Ingelheim, among others
China Antibacterial (Antibiotics) Drugs Market Analysis
China Antibacterial (Antibiotics) Drugs Market is at around $4.09 Bn in 2023 and is projected to reach $6.03 Bn in 2030, exhibiting a CAGR of 5.7% during the forecast period. The market is growing as a result of factors such as rising healthcare expenditures, improving healthcare infrastructure, and an increase in the incidence of infectious diseases. The market is dominated by key players like China Resources Pharmaceutical Group (CR Pharma), Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Jiangsu Hengrui, Pfizer Inc., Roche, Novartis AG, GlaxoSmithKline plc, Abbott Laboratories, Johnson & Johnson, Merck & Co., Inc., and Sanofi S.A.
China Anemia Therapeutics Market Analysis
The China Anemia Therapeutics Market is anticipated to experience a growth from $1.19 Bn in 2022 to $2.664 Bn by 2030, with a CAGR of 10.6% during the forecast period of 2022-2030. The aging population's increased risk of anemia from chronic illnesses, the burden of chronic diseases, rising disposable income that drives up healthcare expenditure, and improved awareness and early detection of anemia are the main drivers in China. The China Anemia Therapeutics Market encompasses various players across different segments, including Pfizer, Roche, GlaxoSmithKline (GSK), Novartis, Sanofi, Amgen, Jiangsu Hengrui Medicine, Guangzhou Baiyunshan Pharmaceutical, Sinopharm Group, Shanghai Pharmaceuticals, etc, among various others.
China Dermatological Therapeutics Market Analysis
China Dermatological Therapeutics Market is at around $3.34 Bn in 2023 and is projected to reach $6.54 Bn in 2030, exhibiting a CAGR of 10.1% during the forecast period. The market is growing as a result of urbanization, increasing elderly population, and growing awareness. The market is dominated by key players like Fosun Pharma (CHN), Sinopharm (CHN), Jiangsu Hengrui Medicine (CHN), CSPC Pharmaceutical Group (CHN), Hualan Biological Engineering (CHN), Harbin Pharmaceutical Group (CHN), Yunna Baiyao Group (CHN), Sino Biopharmaceutical (CHN), Pfizer, Johnson & Johnson, Novartis AG, and GlaxoSmithKline PLC.
China Digital Therapeutics Market Analysis
China Digital Therapeutics Market is at around $0.5 Bn in 2023 and is projected to reach $2.92 Bn in 2030, exhibiting a CAGR of 28.7 % during the forecast period. The market is expanding due to rising chronic diseases, rising healthcare awareness, and government support. The market is dominated by key players like Alibaba Health, WeDoctor, Omada Health Inc., 2Morrow Inc., Livongo Health Inc., WellDoc, Propeller Health, Canary Health, Noom Inc., Akili Interactive Labs Inc., and HYGIEIA.
China Allergy Therapeutics Market Analysis
China Allergy Therapeutics Market was valued at $1865 Mn in 2022 and is estimated to reach $3426 Mn in 2030, exhibiting a CAGR of 7.9% during the forecast period. The need for allergy treatment drugs is being driven by the rising prevalence of allergic disorders and the related health problems. Jiangsu Hengrui Medicine Co., BeiGene, CSPC Pharmaceutical Group Co., Yunnan Baiyao Group Co., Sinopharm Group Co., Guangzhou Fuluo Pharmaceutical Co., Hunan Haier Pharmaceutical Co., Shandong Lukang Pharmaceutical Group Co., North China Pharmaceutical Group Corporation and Shanghai RAAS Pharma Co. are the leading pharmaceutical companies that are presently operating in the market
China Alcohol Addiction Therapeutics Market Analysis
The China Alcohol Addiction Therapeutics Market is valued at around $58 Mn in 2022 and is projected to reach $105 Mn by 2030, exhibiting a CAGR of 7.8% during the forecast period. The primary growth drivers in the China Alcohol Addiction Therapeutic Market are the escalating prevalence of Alcohol Addiction due to rising disposable income and sociocultural shifts, expanding treatment options, and government initiatives recognizing AUD as a public health concern. The key players involved in the research, development, and distribution of Alcohol Addiction Therapeutics in China are Merck & Co., Alkermes, TEVA, Otsuka Pharmaceuticals, Adial Pharmaceuticals, Yabao Pharmaceutical, Tasly Pharmaceutical, China Meheco Corporation, Tonghua Dongbao, Harbin Pharm etc.
China Cardiovascular Drugs Market Analysis
China Cardiovascular Drug Market is at around $11.12 Bn in 2022 and is projected to reach $16.81 Bn in 2030, exhibiting a CAGR of 3.8% during the forecast period. The adoption of digital healthcare is a key factor driving the rise of the China Cardiovascular Drugs Market. The market is dominated by key players like Shanghai Fosun Pharmaceutical Group Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., AstraZeneca, Sanofi, Novartis, and Merck & Co., Inc.
China Acute Lymphocytic Leukemia (ALL) Therapeutics Market Analysis
The China Acute Lymphocytic Leukemia (ALL) Therapeutics Market was valued at US $265 Mn in 2022, and is predicted to grow at (CAGR) of 9.3% from 2023 to 2030, to US $540 Mn by 2030. The key drivers of this industry include a surge in the incidence of acute lymphocytic Leukemia cases, technological advancements, increased government funding initiatives and other factors. The industry is primarily dominated by players such as Walvax, Sinopharm, BeiGene, Simcere among other players
China Autosomal Dominant Polycystic Kidney Disease Therapeutics Market Analysis
The China Autosomal Dominant Polycystic Kidney Disease Therapeutics Market was valued at US$88 Mn in 2022 and is predicted to grow at a CAGR of 7.3% from 2023 to 2030, to US$155 Mn by 2030. The key drivers of this industry include the upward trend in the prevalence of autosomal dominant polycystic kidney disease, healthcare infrastructure, economic growth, and other factors. The industry is primarily dominated by players such as Otsuka, AceLink, Palladio, Reata, Xortx, and Regulus, among others
China Age-Related Macular Degeneration Therapeutics Market Analysis
The China Age-Related Macular Degeneration (AMD) Therapeutics Market was valued at US $0.86 Bn in 2022 and is predicted to grow at a CAGR of 10.40% from 2023 to 2030, to US $1.91 Bn by 2030. The key drivers of this industry include the upward trend in the prevalence of age-related macular degeneration, advancements in treatment, and other factors. Major players in the industry include Regeneron Pharmaceuticals, Novartis, Bayer, Roche, Genentech, and other notable companies
China Adult Malignant Glioma Therapeutics Market Analysis
The China Adult Glioma Therapeutics Market is valued at around $177 Mn in 2022 and is projected to reach $390 Mn by 2030, exhibiting a CAGR of 10.4% during the forecast period. The rising prevalence of gliomas, driven by an aging population, improved diagnostic capabilities, and urbanization, further amplifies the demand for diverse and effective treatment options. Key players in the China Adult Malignant Glioma Therapeutics Market include companies like Merck & Co., Roche, Bristol-Myers Squibb, Novartis, Pfizer, Innovent Pharmaceuticals, BeiGene, Shanghai Junshi Biosciences, Hutchison China MediTech (Chi-Med) etc
China Addiction Therapeutics Market Analysis
China addiction therapeutics market was valued at $812 Mn in 2022 and is estimated to reach $1548 Mn in 2030, exhibiting a CAGR of 8.4% during the forecast period. The increasing awareness and acknowledgment of substance use disorders as significant public health concerns is driving growth in the market for addiction therapy. Some of the leading players operating in the market include Yabao Pharmaceutical Group, Tasly Pharmaceutical Group, China Meheco Corporation, Tonghua Dongbao Pharmaceutical Co., Ltd., Harbin Pharm. Group Sanjing, Zhejiang NHU Company, Shanghai Pharmaceuticals Holding Co., Jiangsu Hengrui Medicine Co., Fosun Pharmaceutical (Group) Co. and 3SBio Inc.
China Actinic Keratosis Therapeutic Market Analysis
China actinic keratosis therapeutic market is projected to develop at a CAGR of 6.4%, increasing from $547 Mn in the year 2022 to $898 Mn by the year 2030. Factors driving the market include the increased acceptance of minimally invasive clinical therapies by the healthcare providers as well as the population, and the availability of suitable medical coverage and the increasing incidence of Actinic Keratosis. Sun Pharmaceuticals, Biofrontera, Nestle, Bausch Health, Novartis, GlaxoSmithKline, Almirall, LLC, LEO Pharma, and Cipher Pharmaceuticals are among the market's key players
China Radiotherapy Market Analysis
By 2030, it is anticipated that the China Radiotherapy Market will reach a value of $991 Mn from $555 Mn in 2022, growing at a CAGR of 7.5% during 2022-30. The Radiotherapy Therapeutics Market in China is dominated by a few domestic players such as Sinopharm, Accuray China Medical Equipment, and Shanghai Elekta Medical Equipment. The radiotherapy market in China is segmented into different types, technologies, procedures, applications, and end-users. The major risk factors associated with awareness of radiotherapy shortage of skilled staff, government initiatives, and reimbursement policy. The demand for China Radiotherapy is increasing on account of the rise in cancer cases in the country.
China Pain Management Devices Market Analysis
This report presents a strategic analysis of the China Pain Management Devices Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the China Pain Management Devices Market, offering unmatched value, accuracy, and expert insights.
China Obesity Drugs Market Analysis
This report presents a strategic analysis of the China Obesity Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges, and future outlook. This is one of the most comprehensive reports about the China Obesity Drugs Market, offering unmatched value, accuracy, and expert insights.
China Lung Cancer Drugs Market Analysis
China's Lung Cancer Drug Market is projected to grow from $0.769 Bn in 2022 to $1.624 Bn by 2030, registering a CAGR of 9.8% during the forecast period of 2022-30. Lung cancer is the most commonly diagnosed cancer in China, and the incidence of lung cancer is increasing in the country, likely due to factors such as smoking and exposure to environmental pollutants. The China lung cancer drug market is dominated by a few large players, including Pfizer, AstraZeneca, and Roche.